Kaken Pharmaceutical signs exclusive distribution agreement for Clenafin/Jublia in Taiwan
Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018.
Latest Developments forMitsubishi Tanabe Pharma Corp
- EU Medicines Agency Says Application For Initial Marketing Authorization For Mitsubishi Tanabe Pharma's Radicava (Edaravone) Has Been Withdrawn
- Health Canada Approves New Drug To Treat Patients With ALS
- R&I affirms Mitsubishi Tanabe Pharma's rating at "A+" and announces stable outlook-R&I
- Mitsubishi Tanabe Pharma completes purchase of NeuroDerm